Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: A post-hoc analysis of observational studies published between 1999 and 2011

Drug Safety

Volumn 34, Issue 12, 2011, Pages 1191-1202

  Hakobyan, Liana ^a,b   Haaijer Ruskamp, Flora M ^a,b   De Zeeuw, Dick ^a,b   Dobre, Daniela ^a   Denig, Petra ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acarbose; Adverse drug reactions; Adverse drug reactions incidence; Antihyperglycaemics; Diabetes mellitus; Glibenclamide; Metformin; Pharmacovigilance

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL FECES; ARTICLE; COMPARATIVE STUDY; CONCURRENT VALIDITY; CONSTIPATION; DIARRHEA; DYSPEPSIA; EMBASE; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HEMATOCHEZIA; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; MEDICAL RECORD; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PATIENT SAFETY; POST HOC ANALYSIS; PRIORITY JOURNAL; STEATORRHEA; STOMACH PAIN; SYSTEMATIC REVIEW; VOMITING;

ACIDOSIS, LACTIC; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL DISEASES; HEALTH PERSONNEL; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PATIENTS; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES;

EID: 81055147684     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11593810-000000000-00000     Document Type: Article

References (45)

1. Greener M. First do no harm: improving drug safety through legislation and independent research. EMBO Rep 2008; 9: 221-4 (Pubitemid 351330983)
2. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29 (5): 385-96
3. Ferrari A, Spaccapelo L, Gallesi D, et al. Focus on headache as an adverse reaction to drugs. J Headache Pain 2009; 10 (4): 235-9
4. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362 (10): 865-9
5. Weingart SN, Gandhi TK, Seger AC, et al. Patient-reported medication symptoms in primary care. Arch Intern Med 2005; 165 (2): 234-40
6. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). ICH topic E2E pharmacovigilance planning. Note for guidance on planning pharmacovigilance activities (CPMP/ICH/5716/03) [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ich/571603en.pdf [Accessed 2011 May 8]
7. European Medicines Agency. Committee for medicinal products for human use (CHMP). ICH topic E1 the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions (CPMP/ICH/375/95) [online]. Available from URL: http://www.ema. europa.eu/pdfs/human/ich/037595en. pdf [Accessed 2011 May 8]
8. US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for industry. Premarketing risk assessment, March 2005 [online]. Available from URL: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126958.pdf [Accessed 2011 May 8]
9. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). ICH topic E6 (R1) guideline for good clinical practice (CPMP/ICH/135/95) [online]. Available from URL: http://www.ema.europa.eu/pdfs/ human/ich/013595en.pdf [Accessed 2011 May 8]
10. Lassila R, Rothschild C, De Moerloose P, et al. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. European Haemophilia Therapy Standardisation Board. Haemophilia 2005; 11 (4): 353-9 (Pubitemid 41030835)
11. Field TS, Gurwitz JH, Harrold LR, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc 2004; 11 (6): 492-8 (Pubitemid 39421733)
12. Basch E, Jia H, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 2009; 101 (23): 1624-32
13. van Grootheest K, van Puijenbroek EP, de Jong-van den Berg LTW. Do pharmacists' reports of adverse drug reactions reflect patients' concerns? Pharm World Sci 2004; 26 (3): 155-9 (Pubitemid 39012583)
14. Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2007; 63 (2): 148-56 (Pubitemid 46072099)
15. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 2004; 22 (17): 3485-90 (Pubitemid 41103654)
16. Gawert L, Hierse F, Zink A, et al. The importance of patient perspective in drug surveillance systems [in German]. Z Rheumatol 2010; 69 (9): 795-802
17. A guideline on summary of product characteristics, September A guideline on summary of product characteristics, September 2009. EudraLex: pharmaceutical legislation notice to applicants and regulatory guidelines medicinal products for human use. Volume 2C regulatory guidelines [online]. Available from URL: http://ec.europa.eu/health/files/eu dralex/vol-2/c/smpc-guideline-rev2-en.pdf [Accessed 2011 May 8].
18. Ligthelm RJ, Borz̀ V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007; 29 (6 Pt1): 1284-92 (Pubitemid 351181208)
19. European Medicines Agency [online]. Available from URL: http://www.ema.europa.eu/ema/[Accessed 2011 Sept 8]
20. Dutch Medicines Evaluation Board [online]. Available from URL: http://www.cbg-meb.nl/CBG/nl/humane-geneesmid delen/ geneesmiddeleninformatiebank/[Accessed 2011 Sept 8]
21. UK electronic Medicines Compendium [online]. Available from URL: http://www.medicines.org.uk/emc/[Accessed 2011 Sept 8]
22. National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), version 4.02, 9 August 2006 [online]. Available from URL: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.02-2009- 09-15-QuickReference-8.511.pdf [Accessed 2010 Oct 12]
23. WellsG A, Shea B, O'ConnellD, et al. TheNewcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [online]. Available from URL: http://www.ohri.ca/programs/clinical-epidemiology/oxford. asp [Accessed 2011 May 8]
24. Asche CV, McAdam-Marx C, Shane-McWhorter L, et al. Evaluation of adverse events of oral antihyperglycaemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging 2008; 25 (7): 611-22 (Pubitemid 351918802)
25. Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004; 20 (4): 565-72 (Pubitemid 38525165)
26. Feher MD, Al-Mrayat M, Brake J, et al. Tolerability of prolonged-release metformin (Glucophage SR) in individuals intolerant to standard metformin: results from four UK centres. Br J Diabetes Vasc Dis 2007; 7 (5): 225-8 (Pubitemid 350055240)
27. Redondo-Capafons S, Garriga Biosca MR, Pla Poblador R. Follow-up of the use of metformin among the high risk population [in Spanish]. Farm Hosp 2005; 29 (6): 364-6 (Pubitemid 43213227)
28. Bytzer P, Talley NJ, Jones MP, et al. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther 2001; 15 (1): 137-42 (Pubitemid 32055594)
29. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161 (13): 1653-9 (Pubitemid 32681147)
30. Chan SP, JiLN, Nitiyanant W, et al.Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-real-life effectiveness and care patterns of diabetes management: the RECAP-DMstudy. Diabetes Res Clin Pract 2010 Aug; 89 (2): e30-2
31. Guagnano MT, Pace-Palitti V, Formisano S, et al. Does holiday hypoglycaemia exist? Panminerva Med 2000; 42 (1): 23-6
32. Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study. Clin Drug Invest 2005; 25 (10): 651-9 (Pubitemid 41330307)
33. Steinsvik EA, Fossa? SD, Axcrona K, et al. Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol 2010; 184 (2): 525-31
34. Ga?wert L, Hierse F, Zink A, et al. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician-and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology 2011; 50 (1): 152-60
35. Jarernsiripornkul N, Kakaew W, Loalukkana W, et al. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf 2009; 18 (3): 240-5
36. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998; 159 (5): 1988-92 (Pubitemid 29190741)
37. Pakhomov SV, Jacobsen SJ, Chute CG, et al. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008; 14 (8): 530-9
38. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 2006; 7 (11): 903-9 (Pubitemid 44615944)
39. Golomb BA, McGraw JJ, Evans MA, et al. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007; 30 (8): 669-75 (Pubitemid 47295826)
40. Fisher S, Bryant SG, Kent TA, et al. Patient drug attributions and postmarketing surveillance. Pharmacotherapy 1994; 14 (2): 202-9 (Pubitemid 24108304)
41. Bent S, Padula A, Avins AL. Brief communication: better ways to question patients about adverse medical events. A randomized, controlled trial. Ann Intern Med 2006; 144 (4): 257-61 (Pubitemid 46768208)
42. Chrysant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens 2008; 10 (9): 716-22
43. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140 (10): 795-801 (Pubitemid 38623529)
44. Buurma H, De Smet PA, Kruijtbosch M, et al. Disease and intolerability documentation in electronic patient records. Ann Pharmacother 2005; 39 (10): 1640-6 (Pubitemid 41393122)
45. Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 2002; 1 (1): 71-8